Localized aggressive periodontitis (LAgP) is a chronic inflammatory disease characterized by severe destruction of periodontal tissues surrounding the first molars and incisors. LAgP subjects produce large amounts of immunoglobulin G2 (IgG2) antibody against oral pathogens, and this response is inversely correlated with the severity of disease. We previously demonstrated that platelet-activating factor (PAF) is required for optimal IgG2 responses. The present investigation was designed to determine the mechanism of IgG2 induction by PAF. Exogenous PAF acetylhydrolase suppressed approximately 80% of pokeweed mitogenstimulated IgG2 production, confirming that PAF is essential for optimal responses. PAF-activated leukocytes produced gamma interferon (IFN-␥), a Th1 cytokine that has been associated with IgG2 responses in previous studies. The monocyte-derived cytokines interleukin-12 (IL-12) and IL-18 are upstream of IFN-␥ production, and IgG2 production was suppressed by neutralizing antibodies against these proteins. In addition, PAF induced monocyte-derived dendritic cells (DC) but not macrophages (M⌽) to secrete IL-12 and IL-18. This observation was interesting because monocyte differentiation in LAgP subjects is skewed to the DC phenotype. Although other investigators have implicated IFN-␥ in IgG2 production, its precise role in this response is controversial. Our studies suggest that IFN-␥ induces isotype switching to IgG2 but only in concert with the Th2 cytokine IL-4. Thus, it appears that the unique PAF metabolism of LAgP monocytes or DC promotes Th1 responses that are essential for optimal IgG2 antibody production. As IgG2 antibodies opsonize oral bacteria and promote their clearance and destruction, these alterations in PAF metabolism may be essential for limiting disease severity in LAgP patients.
Localized aggressive periodontitis (LAgP) is classified as an early-onset form of periodontitis due to its propensity to develop in adolescents around the time of puberty. It is characterized by severe destruction of supporting periodontal structures, primarily around the incisors and primary molars (2, 34) . The disease clearly has a bacterial origin and several oral pathogens have been linked to the disease, most notably Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis (11, 58) . However, as LAgP is an inflammatory disorder, the host response also contributes to its pathogenesis and in fact may dictate the pattern and severity of the disease.
Several immunological anomalies have been noted in LAgP subjects. For example, LAgP neutrophils exhibit reduced chemotaxis, oxidative burst, and calcium responses compared to neutrophils from periodontally healthy (nonperiodontitis [NP] ) individuals (15, 25, 46) . The monocytes of LAgP subjects exhibit exaggerated responses to bacterial lipopolysaccharides and produce large amounts of tumor necrosis factor and prostaglandin E 2 (PGE 2 ) (44) . Immunoglobulin production in LAgP subjects is also somewhat abnormal, as LAgP patients have ϳ35% more serum immunoglobulin G2 (IgG2) antibody than do race-matched NP subjects. The levels of this antibody reactive with A. actinomycetemcomitans and P. gingivalis are inversely correlated with the severity of the disease (9, 22, 33) , suggesting that IgG2 antibodies are protective and promote the phagocytosis and clearance of oral pathogens. The IgG2 antibody response tends to be elicited against carbohydrate antigens, and the oral pathogens (A. actinomycetemcomitans in particular) express serotype-specific carbohydrates that can be opsonized (10, 11, 56, 57) .
In recent years, we have gained several insights into the mechanisms that underlie the apparent increase in IgG2 antibody production in LAgP subjects. These studies have been conducted with in vitro cultures of peripheral blood leukocytes (PBL) stimulated with a polyclonal activator, pokeweed mitogen (PWM) (59) . LAgP PBL stimulated in this system produce larger amounts of IgG2 antibody than do NP PBL, but IgG1 production is similar for NP and LAgP PBL. These observations are consistent with the levels of IgG1 and IgG2 antibodies in the circulation of LAgP and NP subjects. This culture system has been used to delineate the contributions of the major cell types in PBL (B cells, T cells, monocytes) to the IgG2 antibody response. For example, when LAgP monocytes are added to NP T and B cells, a dose-dependent induction of IgG2 is observed. This effect can be recreated with the cell-free supernatants of LAgP monocytes, suggesting that these cells secrete mediators that augment IgG2 production (27) . In contrast, NP monocytes do not augment IgG2 antibody production. Together, these data suggest that LAgP monocytes secrete soluble mediators that augment the IgG2 antibody response.
Activated monocytes produce a variety of immunoregulatory cytokines and lipid mediators, and several of these appear to have roles in the IgG2 response. For example, PWM-stimulated IgG2 production is suppressed by neutralizing antibodies against interleukin-1-␣ (IL-1-␣) or IL-1-␤. Neither cytokine can compensate for the other, suggesting that IL-1-␣ and IL-1-␤ have nonredundant roles in the IgG2 response (26) . The lipid mediator PGE 2 selectively induces IgG2 and appears to be essential for optimal induction, as inhibitors of PGE 2 synthesis block ϳ80% of PWM-stimulated IgG2 production (27) . Interestingly, the lipid mediator platelet-activating factor (PAF; 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) appears to have one of the most critical roles in the IgG2 response. PAF receptor antagonists suppress nearly 90% of IgG2 production, and a neutralizing anti-PAF antibody has a similar effect (27) . As the biological activities of PAF are mediated through its interaction with a receptor that is expressed on the surfaces of a variety of cells including B cells, T cells, and monocytes (5, 8, 38, 40, 47) , the effects of PAF on the IgG2 response may be mediated through the activation of any or all of these cell types. The present investigation was performed to delineate the mechanism by which PAF induces IgG2. Our studies indicate that PAF promotes Th1 responses through the activation of monocytes and lymphocytes but does not directly induce isotype switching to IgG2 by B cells. The PAF-induced Th1 response culminates in the production of gamma interferon (IFN-␥), the cytokine most closely associated with IgG2 production (30, 31) . Given the elevated levels of PAF that are present in the cells and tissues of periodontitis patients (18, 21, 35, 37) , this may account for the high levels of IgG2 that are present in their sera.
MATERIALS AND METHODS
Human subjects. Human studies were performed in compliance with all relevant federal guidelines and the institutional policies of Virginia Commonwealth University, Richmond. Buffy coat preparations were obtained from Virginia Blood Services (Richmond, Va.) and were used within 24 h of blood draw. In the IgG2 experiments, subjects for study were obtained by the Clinical Research Center for Periodontal Disease, School of Dentistry, Virginia Commonwealth University. Patients with LAgP were 35 years old or less and had localized patterns of severe periodontal destruction limited to the first molar or incisor teeth and up to two additional teeth. The NP control subjects were age-(within 5 years) and race-matched and had no evidence of attachment loss, except for recession on the buccal surface of anterior teeth at no more than one site and no pockets greater than 3 mm. All subjects were nonsmokers.
PAFAH purification. Plasma PAF acetylhydrolase (PAFAH) was partially purified using a previously described protocol (50) . Briefly, 100 ml of 4% sodium phosphotungstate (pH 7.0) was added to 1 liter of citrated human plasma. Magnesium chloride was added to 45 mM and the resulting solution was centrifuged at 6,000 ϫ g for 10 min. The resultant pellet was resuspended in 1 liter of 0.2% unbuffered sodium citrate, and the lipoproteins were reprecipitated by the addition of MgCl 2 to 60 mM and 10 g of NaCl. The reprecipitation was repeated, and the final pellet (containing low-density lipoprotein and very-lowdensity lipoprotein) was resuspended in 1 liter of 10 mM potassium phosphate (pH 6.8) containing 0.1% Tween 20. The pellet was stirred overnight to solubilize lipoprotein-associated PAFAH, and aliquots were stored at Ϫ20°C until use. In some cases, the purified PAFAH was treated with 4-[aminoethyl]benzenesulfonyl fluoride (AEBSF) to inhibit catalytic activity. The protocol for AEBSF treatment was based on a previous report (36) and involved incubation of purified PAFAH with 0.1 mM AEBSF for 30 min at 37°C. After the incubation, the PAFAH was dialyzed against phosphate-buffered saline (PBS) at 4°C overnight and then aliquoted and stored as described above. To determine the extent of inhibition, PAFAH activity was quantified with an assay that has previously been described (1) . The AEBSF-treated PAFAH samples contained less than 1% residual catalytic activity (data not shown).
Isolation of leukocytes from peripheral blood. Heparinized or citrated human peripheral blood (30 ml) was layered over 15 ml of lymphocyte separation media (Cappel) and centrifuged at 400 ϫ g for 30 min. Peripheral blood leukocytes (PBL) were collected from the interface and washed with RPMI media. To obtain adherent monocytes, the PBL were cultured on plastic plates for 1 h at 37°C in 1 ml of RPMI containing 10% heat-inactivated fetal calf serum. Extensive washing was performed to remove nonadherent cells. In all cases, cell viability was at least 90%.
Macrophage (M⌽) cell cultures. Adherent monocytes were cultured for 7 days in RPMI containing 10% heat-inactivated human AB serum (Biowhittaker), 50 g of gentamicin/ml (Invitrogen Life Technologies), 2 mM glutamine (Invitrogen Life Technologies), and 1,000 U of recombinant human M⌽ colony-stimulating factor (rhM-CSF) (R&D Systems) to induce differentiation to the M⌽ phenotype. Cell cultures were maintained at 37°C, 7.5% CO 2 , and 100% humidity.
Monocyte-derived dendritic cell (DC) cultures. Adherent monocytes were cultured for 7 days in RPMI containing 10% heat-inactivated fetal calf serum, 50 g of gentamicin/ml (Invitrogen Life Technologies), and 2 mM glutamine (Invitrogen Life Technologies) in the presence of 500 U of rhIL-4/ml and 800 U of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF; R&D Systems)/ml. Cell cultures were maintained at 37°C, 7.5% CO 2 and 100% humidity.
Naïve B-cell separation. CD19 ϩ B cells were positively selected from PBL by magnetic labeling using a CD19 Multisort kit (Miltenyi Biotec, Auburn, Calif.) according to the manufacturer's instructions. CD19 microbeads were then released from B cells with the release reagent provided with the Multisort kit. Then, purified B cells were subjected to a second positive selection to isolate naïve B cells. In the second round of magnetic labeling, B cells were labeled with biotin-conjugated mouse anti-human IgD antibodies (Southern Biotech) at 1 g/10 6 cells at 4°C for 10 min. This was followed by incubation with streptavidin microbeads (Miltenyi Biotec) at 10 l/10 7 cells for 15 min. IgD ϩ naïve B cells were then positively selected according to the manufacturer's instructions (Miltenyi Biotec). The purity of the naïve B cells was analyzed by flow cytometric analysis with the following fluorescent antibodies: fluorescein isothiocyanate (FITC)-labeled anti-human CD19, FITC-labeled anti-human IgM, FITC-labeled anti-human CD3, or FITC-labeled anti-human CD14 (Pharmingen). The data were collected with a FACScan instrument (Becton-Dickinson) using Cell Quest Pro software and analyzed with WinMDI 2.8 software. All naïve B-cell preparations exceeded 95% CD19
ϩ IgD ϩ cells (data not shown). Naïve B-cell culture for analysis of isotype switching. CD40 ligand (CD40L)-transfected 293 cells (2.5 ϫ 10 4 ; kindly provided by Lori Covey, Rutgers University) were added to wells in a 96-well plate and irradiated with 4,000 rads. Then, 5 ϫ 10 4 naïve B cells/well were added, and the cells were cultured in RPMI media containing 10% heat-inactivated fetal calf serum, 50 g of gentamicin/ml (Invitrogen), and 2 mM glutamine (Invitrogen) in a 96-well plate in a 300-l final volume at 37°C in 7.5% CO 2 and 100% humidity. The cells were treated with 50 nM PAF (Avanti Polar Lipids), PAF vehicle (dimethyl sulfoxide [DMSO]), or 500 U of rhIFN-␥ (R&D Systems)/ml in the absence or presence of 100 U of rhIL-4 (R&D Systems)/ml for 5 days.
RT PCR. On day 5, the cells were harvested in 0.5 ml of Trizol (Invitrogen), and RNA extraction was performed according to the manufacturer's instructions. Total RNA (0.5 to 1.0 g) was used in cDNA synthesis with a Thermoscript reverse transcriptase (RT) PCR system (Invitrogen). The reaction was primed with oligo(dT) 20 , and 5 l of the 20-l RT reaction was used to amplify ␥1 and ␥2 germ line transcripts or mature transcripts in the PCR. To amplify ␥1 and ␥2 germ line transcripts (I H -C H ), the following primers (described in reference 31) were used: sense ␥1, 5Ј ACGAGGAACATGACTGGATGC 3Ј; antisense ␥1, 5Ј TGAGTTTTGTCACAAGATTTGGG 3Ј; sense ␥2, 5Ј TCTCAGCCAGGACC AAGGAC 3Ј; antisense ␥2, 5Ј ACTCGACACAACATTTGCG 3Ј. The 5Ј primers were complementary to sequences in the I␥1 or I␥2 region and the 3Ј primers were complementary to sequences in the hinge region of C␥1 or C␥2. RT PCR was performed using the hot start method for 30 cycles, with each cycle consisting of 45 s at 94°C, 1 min at 60°C, and 90 s at 72°C (31) . The ␥1 and ␥2 mature transcripts (V H -DJ H -C H ) were amplified with primers described in reference 12. The antisense ␥1 primer was 5Ј GTTTTGTCACAAGATTTGGGCTC 3Ј, the antisense ␥2 primer was 5Ј GTGGGCACTCGACACAACATTTGCG 3Ј, and the sense primer for both ␥1 and ␥2 was in framework region 3 and was 5Ј GACACGGCTGTGTATTACTGTGCG 3Ј. The mature transcripts were amplified in RT PCRs for 30 cycles consisting of 1 min at 94°C, 1 min at 68°C, and 1 min at 72°C. PCR products were electrophoresed in 1.2% agarose gels containing ethidium bromide. The sizes of PCR products were identified using a 100-bp DNA ladder (Invitrogen). The size of the ␥1 germ line transcript is 535 bp, the ␥2 germ line transcript is 344 bp, and the ␥1 and ␥2 mature transcripts are both VOL. 11, 2004 PLATELET-ACTIVATING FACTOR AND IgG2 ANTIBODY 721 416 bp. The amplified products were quantified with a Fluorochem 8800 imager (Alpha Innotech). Cytokine assays. M⌽, monocyte-derived DCs, and nonadherent PBL were cultured overnight in the presence or absence of PAF (Avanti Polar Lipids) in RPMI containing 5 mg of Fraction V bovine serum albumin (Sigma, St. Louis, Mo.)/ml. The preparation of PAF was determined to be essentially endotoxin free (Ͻ0.33 pg of endotoxin/ml) with a Kinetic-QCL LAL testing kit from Biowhittaker. Cell-free supernatants were harvested and screened for IL-12, IL-18, and IFN-␥ with enzyme-linked immunosorbent assay (ELISA) kits from Biosource (IL-12) or R&D Systems (IL-18 and IFN-␥). The cell monolayers were solubilized with 0.5% Triton X-100 and harvested to quantify protein mass (Bio-Rad dye binding assay). Cytokine production was normalized to protein recovery. The data are presented as n-fold induction, which is the ratio of cytokine production by PAF-treated cells to production by resting cells.
Antibody production. PBL (10 6 per sample) were cultured in RPMI 1640 (Mediatech, Herndon, Va.) supplemented with 10% heat-inactivated fetal bovine serum (HyClone, Logan, Utah), 2 mM glutamine, 100 U of penicillin/ml, and 100 mg of streptomycin sulfate (Sigma)/ml and cultured in 75-mm tubes (Falcon, Lincoln Park, N.J.) in a volume of 1 ml/tube at 37°C in a humidified atmosphere of 5% CO 2 . Nine microliters of PWM was added to the cell cultures to induce antibody production. In some experiments, the cells were cultured in the presence of neutralizing antibodies (R&D Systems) against IL-12 (100 g/ ml) or IL-18 (50 g/ml) or an isotype-matched control antibody. The cultures were incubated for 7 days, and then supernatant fluids were collected and assayed for IgG2 as outlined below.
IgG2 assays. IgG2 levels in supernatant fluids were determined by a sandwich ELISA as described previously (4) . Briefly, Fc-specific goat anti-mouse antibody (10 l/ml) (ICN, Aurora, Ohio) in pH 9.6 carbonate buffer was used to coat the microtiter plates (Dynex, Chantilly, Va.). Mouse anti-human IgG2 monoclonal antibody (1 g/ml) (Sigma) was then added to the plates to serve as capture antibody. The plates were incubated overnight at 4°C and washed, and bovine serum albumin-PBS was applied to minimize nonspecific binding. A known standard for human IgG2 antibody and the culture supernatant fluids were applied to different wells in plates and incubated for 1 h at room temperature. Horseradish peroxidase-conjugated goat anti-human immunoglobulin (Sigma) was added and the plates were incubated for 1 h at room temperature. The plates were washed three times with PBS containing 0.05% Tween 20 between each step. The color was developed using O-phenylenediamine dihydrochloride (Sigma) as substrate. Optical density at 450 nm was measured using a microplate reader (Dynex). The IgG2 concentration in each test sample was calculated using the standard curve generated in each assay.
Statistical analyses. All experiments were replicated with at least three different individuals or preparations of cells. Each experimental analysis was performed in triplicate, and the mean and standard deviations of each set of replicates were determined. For the neutralizing antibody experiments, statistical significance was determined through unpaired t tests, with a P of Ͻ0.05 as the cutoff for significance. In the cytokine experiments, the data were not normally distributed, so analyses were performed on log transforms. Responses within an experiment were modeled with a mixed-model repeated-measures analysis of variance. For the experiments with exogenous PAFAH, the percentage of control was analyzed using the difference of the logs of the two values in a repeatedmeasures mixed-model analysis (SAS version 8). The predicted values and confidence intervals were then back-transformed to the original scale for presentation.
RESULTS
Exogenous PAFAH selectively suppresses IgG2 production. The monocytes of LAgP subjects contain lower levels of PAFAH (the phospholipase that catabolizes PAF) than do monocytes from periodontally healthy (NP) subjects (1). LAgP leukocytes produce large amounts of IgG2 when stimulated in vitro (59), and we hypothesized that this might be a reflection of the low levels of PAFAH that are produced by LAgP monocytes. To test this hypothesis, we determined the effect of exogenous PAFAH on PWM-stimulated IgG2 production. Various doses of partially purified PAFAH were added to PBL stimulated with 9 l of PWM/ml. Cell-free supernatants were collected and IgG2 was quantified with an ELISA. As shown in Fig. 1 , PAFAH suppressed IgG2 production in a dose-dependent manner. The exogenous enzyme suppressed IgG2 production by up to ϳ80%. This degree of suppression is similar to that observed with a PAF receptor antagonist and an anti-PAF antibody (27) . Catalytically inactive PAFAH (prepared by treating the enzyme with the serine-modifying agent AEBSF) had no effect on IgG2 production. Exogenous PAFAH did not suppress IgG1 production (data not shown), consistent with previous data showing the IgG2-specific effects of PAF (27) .
PAF induces Th1-associated cytokines that are essential for optimal IgG2 responses. The data in Fig. 1 supported the hypothesis that PAF plays an essential role in the IgG2 response in LAgP subjects. We next sought to determine the mechanism of IgG2 induction by PAF and initially focused our attention on its effects on monocytes. Monocytes are the precursors of two important immunoregulatory cell types, DCs and M⌽, and are known to respond to PAF (1) . It was recently demonstrated that LAgP monocytes exhibit a propensity to differentiate into DCs, compared to NP monocytes that primarily differentiate into M⌽ (4). Enriched cultures of DCs and M⌽ were prepared by culturing adherent NP monocytes in IL-4 plus GM-CSF or in M-CSF, respectively. After differentiation, the cells were treated with various doses of PAF. The cell-free supernatants were collected and screened for IL-12 and IL-18, two proinflammatory cytokines that are essential for optimal IgG2 antibody responses. PBL were cultured with PWM in the presence of neutralizing antibodies against IL-12 (100 g/ml) and IL-18 (50 g/ml) or an isotype-matched control antibody. Culture supernatants were harvested and screened for IgG2. An isotype-matched control antibody had no effect on IgG2 production. The data were compiled from three independent experiments with different individuals. Both anti-IL-12 and anti-IL-18 suppressed IgG2 production (P Ͻ 0.05, Student's t test). IgG2 production was 28% Ϯ 5% and 23% Ϯ 6% of control production in the anti-IL-12-and anti-IL-18-treated cultures, respectively. As shown in Fig. 2A , PAF induced DCs to secrete IL-12 while M⌽ made no comparable response. A similar trend was observed for IL-18 (Fig. 2B) , although the IL-18 response of PAF-treated DCs was not as robust as was the IL-12 response. The involvement of IL-12 and IL-18 in the IgG2 response is somewhat incongruous with the accepted paradigm of T-cell biology that segregates T-cell immunity into Th1 responses (associated with cell-mediated immunity and inflammation) and Th2 responses (associated with antibody responses) (51). However, other investigators have shown that IFN-␥, the prototypical Th1 cytokine, is essential for IgG2 antibody responses (30, 31) . Thus, another potential role for PAF in the IgG2 response may be the induction of IFN-␥ production by lymphocytes. To test this hypothesis, we treated nonadherent PBL with various doses of PAF, collected the cell-free supernatants, and screened for IFN-␥. These cultures contain primarily lymphocytes, although a limited number of monocytes may be present as well. In these lymphocyte-enriched cultures, PAF induced IFN-␥ in a dosedependent manner (Fig. 3) . It is possible that this IFN-␥ production is mediated through direct interactions between PAF and lymphocytes. Alternatively, residual monocytes in the cultures may be activated by PAF and produce IL-12 and IL-18 that then act on lymphocytes to induce IFN-␥. Together with the analysis of IL-12 and IL-18, these observations suggest that (5, 20) . Therefore, we considered the possibility that PAF might act directly on B cells to induce isotype switching to IgG2. To address this hypothesis, naïve IgD ϩ B cells were stimulated with CD40L in the presence of various amounts of PAF, and RNA was isolated and screened for the presence of ␥1 and ␥2 germ line transcripts, essential prerequisites to isotype switching to IgG1 and IgG2, respectively. Raw data from a representative experiment are shown in Fig. 4A and a quantification of these data are shown in Fig. 4B . As expected, unstimulated naïve B cells expressed neither ␥1 nor ␥2 germ line transcripts (data not shown). However, stimulation with CD40L induced both ␥1 and ␥2 germ line transcripts. Similar ratios of ␥1 to ␥2 germ line transcripts were observed when CD40L-stimulated B cells were cultured with PAF, methylcarbamyl PAF (cPAF; nonhydrolyzable PAF analog), or vehicle control (DMSO). Other investigators have demonstrated that IL-4 synergizes with other cytokines to isotype switching (19, 23, 54) . Therefore, we investigated the possibility that IL-4 might be required for PAF-induced isotype switching to IgG2. However, IL-4 coculture did not alter the ratio of ␥1 to ␥2 germ line transcripts in PAF-or cPAF-treated B cells (data not shown). These data suggest that PAF does not act directly on B cells to promote isotype switching but rather that the induction of IgG2 by PAF is mediated through its ability to activate accessory cells and induce the Th1 response and IFN-␥.
Although the necessity of IFN-␥ for IgG2 production is well established, the mechanism is under dispute, with some studies suggesting a role in isotype switching while others suggest that IFN-␥ affects later steps in the differentiation of IgG2-producing B cells (30, 31) . Therefore, we performed experiments to investigate the role of IFN-␥ in the IgG2 response. CD40L-stimulated naïve B cells were used to determine if IFN-␥ induced ␥2 germ line transcription. Similar to the experiment shown in Fig. 4 , neither ␥1 nor ␥2 germ line transcripts were present in unstimulated naïve B cells (data not shown), but both were induced upon stimulation with CD40L ( Fig. 5A and B) and were further induced in cells cultured with CD40L in the presence of IL-4 (compare lanes 3 and 4 to lanes 7 and 8) . The ratio of ␥1 to ␥2 germ line transcripts was unchanged when CD40L-stimulated B cells were cultured with IFN-␥ or IL-4 alone. However, both ␥2 germ line (Fig. 5A and B) and mature (Fig. 5C ) transcripts were induced when naïve B cells were treated with IL-4 and IFN-␥ together. Thus, it appears that the role of PAF in the IgG2 response is in the induction of the Th1 cytokine IFN-␥ that then synergizes with IL-4 to induce isotype switching to IgG2.
DISCUSSION
In previous studies, it was demonstrated that PAF is essential for optimal IgG2 antibody responses (27) . The goal of this investigation was to delineate the mechanism by which PAF induces IgG2. Our data indicate that PAF activates monocytes to produce the Th1-associated cytokines IL-12 and IL-18 ( Fig.  2) and potentially activates lymphocytes to produce IFN-␥ FIG. 1. Exogenous PAFAH suppresses IgG2 production. PBL were cultured for 7 days with 9 l of PWM in the presence or absence of active or inactive PAFAH. Cell-free supernatants were collected and IgG2 antibody levels were quantified as described in Materials and Methods. The data are presented as percentages of control IgG2 production, where the control is PBL cultured with PWM in the absence of exogenous PAFAH. The data shown are compiled from four to six independent experiments with PBL from different individuals. Error bars indicate 95% confidence intervals. The dotted line indicates control response (100%). *, IgG2 production was lower in active PAFAH-treated samples (P Ͻ 0.05).
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PLATELET-ACTIVATING FACTOR AND IgG2 ANTIBODY 723 (Fig. 3) , a Th1 cytokine that other investigators have implicated in the induction of IgG2 (30, 31) . We also show that IFN-␥ induces B cells to undergo isotype switching to IgG2, but only in concert with the Th2 cytokine IL-4. Thus, both Th1 and Th2 cytokines are necessary for optimal IgG2 production. This requirement for the two classes of helper T-cell cytokines distinguishes IgG2 from other isotypes of antibody in the human system. The commonly accepted paradigm dictates that antibody responses are induced by Th2 cytokines while Th1 cytokines are associated with inflammation and cell-mediated immunity (51) . However, there is ample evidence in the human system for the dependence of IgG2 antibody on IFN-␥, the quintessential Th1 cytokine (30, 31) . Similarly, in the murine system, exogenous IFN-␥ induces IgG2a and IgG3, and these isotypes are suppressed when B cells are cultured in the presence of neutralizing antibodies against IFN-␥ (6, 16, 32, 48). These observations are consistent with the recently reported requirement for the Th1-associated transcription factor T-bet in isotype switching to IgG2a and for the production of IgG2a, IgG2b, and IgG3 in the mouse system (39) . Similarly, T cells from ICOS-deficient mice produce large amounts of IFN-␥, and the IgG3 response against T-independent antigens is elevated in these mice (52) . Although T cells are required for optimal IgG2 responses in our PWM-stimulated system (59), it remains possible that T cells are not the only source of IFN-␥ in our cell cultures. For example, activated natural killer (NK) cells produce large amounts of this cytokine (14) . Thus, it is possible that the IL-12 produced by PAF-stimulated DCs activates NK cells that then produce IFN-␥ and thereby induce IgG2.
The mechanism of the IFN-␥-mediated induction of human IgG2 remains somewhat controversial. By using preparations of human PBL, Kawano et al. (30) demonstrated that IFN-␥ induced IgG2 secretion but that this did not occur if surface IgG2 ϩ B cells were depleted from the PBL. This observation suggests that the effects of IFN-␥ are limited to cells that have already committed to the IgG2-producing lineage and there-FIG. 2. DCs produce Th1-associated cytokines in response to PAF. DCs and M⌽ (MO) were prepared from adherent monocytes as described in Materials and Methods. The cells were cultured overnight with various doses of PAF, and cell-free supernatants were harvested and screened for IL-12 (A) or IL-18 (B). Cytokine levels were normalized for protein recovery, and the data are presented as n-fold induction of cytokine over control (cells cultured in DMSO, the vehicle). The data shown are compiled from two to four independent experiments with monocytes from different individuals. PAF induced DCs to produce both IL-12 and IL-18 (P Ͻ 0.05) in a dose-dependent manner, while M⌽ did not make this response.
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fore occur after isotype switching has occurred. In contrast, Kitani and Strober (31) have shown that exogenous IFN-␥ induces ␥2 germ line transcription, an essential event that must take place before isotype switching to IgG2 can occur. Our observations are more consistent with those of Kitani and Strober, as IFN-␥ enhanced the levels of ␥2 germ line transcripts in our IgD ϩ naïve B cells while suppressing ␥1 germ line transcription (Fig. 5A ) and induced ␥2 mature transcripts ( CL01 B cells cultured with CD40L alone. Thus, although it is possible that the apparent IL-4 dependence of ␥1 mature transcription is an artifact, our results for ␥2 mature transcripts are consistent with other published data suggesting that IL-4 is essential for this event.
Our data suggest that the Th2 cytokine IL-4 is required for IFN-␥-mediated induction of ␥2 isotype switching. Other investigators have demonstrated the induction of ␥2 isotype switching by IL-4, and this is at least partially attributed to the effects of IL-4 as B-cell growth factor (12) . As LAgP is an inflammatory disorder associated with elevated PAF and Th1 cytokines, one might question the availability of IL-4 in LAgP subjects. It has been reported that LAgP monocytes produce large amounts of PGE 2 , a proinflammatory lipid mediator that is also known to mediate bone resorption by activating osteoclasts (45) . We have recently demonstrated that PGE 2 acts on lymphocytes to elicit IFN-␥ (53). Interestingly, PGE 2 also has anti-inflammatory properties, as it both induces Th0 cells to adopt the Th2 phenotype and suppresses the differentiation of Th1 cells (24, 28, 29) . Thus, we predict that activated LAgP monocytes secrete PGE 2 that then drives Th2 cells to produce the IL-4 required to synergize with IFN-␥ to induce isotype switching to IgG2. This hypothesis may appear inconsistent with the inflammatory Th1 nature of LAgP and with previous reports of a strong Th1 bias in LAgP (43, 53) . However, we suggest that LAgP subjects produce both IFN-␥ and IL-4, with the Th1 cytokine dominating the response, and that relatively low levels of IL-4 are sufficient to induce isotype switching.
PAF is a bioactive phospholipid that is primarily produced by activated monocytes and neutrophils (40) . The biological activities of PAF are mediated through its interaction with a Gi-coupled receptor that is expressed on the surfaces of a variety of cells. Many of the biological activities of PAF are associated with the inflammatory response. For example, PAF induces the activation and aggregation of platelets, eicosanoid production by monocytes, the release of proinflammatory cytokines from monocytes and neutrophils, and the adhesion of activated leukocytes to the endothelium (13) . LAgP is an inflammatory disease and several lines of evidence suggest that PAF has roles in its pathogenesis. The potential connection between PAF and periodontitis was recognized as far back as 1989, when it was reported that PAF levels were elevated in inflamed gingival tissues (37) . Since that initial report, elevated PAF levels have been demonstrated in the saliva, gingival crevicular fluid, and gingival tissues of periodontitis patients (18, 35) , including subjects with LAgP. It is likely that the high levels of PAF observed in LAgP and other periodontal diseases are at least partially due to increased synthesis, as activated inflammatory cells are the primary sources of PAF (40) . However, PAF levels are also influenced by the rate of catabolism. PAF is catabolized by PAFAH, a secreted phospholipase A 2 that is primarily produced by monocytes. When monocytes differentiate into M⌽, PAFAH expression increases nearly 100-fold (17) . We have recently demonstrated that another form of differentiated monocyte, the monocyte-derived DC, expresses very low levels of PAFAH and secretes almost none of this activity. As a result, DCs secrete large amounts of PGE 2 in response to PAF, while the response of M⌽ is much more limited (1). Similar results were obtained in the present investigation, as PAF stimulated DCs but not M⌽ to produce IL-12 and IL-18 ( Fig. 2A and B) . These observations are of particular interest because monocyte differentiation appears to be skewed to the DC phenotype in LAgP subjects (4) . Indeed, PAFAH levels are lower in the adherent monocytes of LAgP subjects than in monocytes from race-matched NP controls (1). Thus, we predict that the skewing of monocyte differentiation in LAgP subjects results in low levels of the catabolic enzyme PAFAH and that this allows the bioactive lipid PAF to accumulate and thereby activate inflammatory cells. A positive correlation has been observed between PAF levels and disease severity, which suggests that PAF may have a causative role in the disease process (21, 35) . Indeed, periodontal therapies not only reduce the indices of disease but also result in reductions in salivary PAF (41) . Furthermore, PAF activates monocytes and thereby elicits the production of PGE 2 (3, 7, 55), another lipid mediator that then activates osteoclasts and thereby elicits bone resorption. Together, these data strongly suggest that there is a correlation between PAF and disease progression in LAgP. However, given its roles in the protective IgG2 antibody response, we contend that PAF should be viewed as a "doubled-edged sword." IgG2 levels are elevated in LAgP subjects, and patients with the highest titers of IgG2 reactive with A. actinomycetemcomitans and P. gingivalis tend to have fewer sites with Ն2 mM attachment loss (9, 22) . Thus, we suggest that the high levels of PAF that accumulate in LAgP subjects both contribute to disease progression and the production of protective IgG2 antibodies. Carbohydrate antigens tend to elicit the IgG2 response (42, 49) . Both A. actinomycetemcomitans and P. gingivalis, the oral pathogens most closely associated with LAgP, are rich in carbohydrate antigens, and much of the IgG2 antibody response in LAgP is directed against these organisms (10, 11, 57) . Thus, the adaptive immune system in LAgP subjects takes advantage of the chronic inflammation associated with the disease to generate a protective antibody response. This is largely dependent on the unique phenotype of the LAgP monocyte and its impact on PAF metabolism.
